// Migrated from Contentful resource "how-non-dispensing-pharmacies-can-improve-the-patient-access-journey" (Gatsby node 8b5e1ce3-3b1a-53fd-bdbe-6c0b020a533e) on 2026-10-13.
// Source: https://phil.us/page-data/how-non-dispensing-pharmacies-can-improve-the-patient-access-journey/page-data.json
import React from "react";
import type { HeadFC } from "gatsby";
import { SeoMeta } from "components/common/Seo/SeoMeta";
import { JsonLd } from "components/common/Seo/JsonLd";
import { articleSchema } from "utils/seo/schema";
import { StaticBlogLayout, BlogA, BlogH2, BlogLI, BlogP, BlogUL } from "components/Blog/StaticBlogLayout/StaticBlogLayout";

const PATH = "/how-non-dispensing-pharmacies-can-improve-the-patient-access-journey/";
const TITLE = "How Non-Dispensing Pharmacies can Improve the Patient Access Journey";
const DESCRIPTION = "Discover how non-dispensing pharmacies can improve the prescription access experience for patients and providers, and create unparalleled brand success for specialty-lite manufacturers";
const OG_IMAGE = "https://phil.us/images/blog/og/6-Company_News.webp";

export const Head: HeadFC = () => (
  <>
    <SeoMeta title={TITLE} description={DESCRIPTION} path={PATH} type="article" image={OG_IMAGE} />
    <JsonLd data={articleSchema({ path: PATH, headline: TITLE, description: DESCRIPTION, image: OG_IMAGE })} />
  </>
);

const Page: React.FC = () => (
  <StaticBlogLayout title={TITLE} hero={{ src: "/images/blog/6-Company_News.svg", alt: "" }}>
    <BlogP>{"Patients struggling with complex medical conditions face a growing number of barriers to access, afford, and adhere to the innovative therapies their providers prescribe. In 2022, out-of-pocket costs led to the "}<BlogA href="https://www.mgma.com/federal-policy-resources/mgma-annual-regulatory-burden-report-2023"><u>abandonment of 94 million prescriptions</u></BlogA>{". And in a 2023 survey, "}<BlogA href="https://www.mgma.com/federal-policy-resources/mgma-annual-regulatory-burden-report-2023"><u>97% of medical practices</u></BlogA>{" said their patients had experienced care delays or denials due to increased prior authorization requirements. "}</BlogP>
    <BlogP>{"Life sciences manufacturers continue to seek new ways to improve the patient access journey to make it easier for patients to start on therapy.  One model in particular, non-dispensing pharmacies, can be a powerful tool to break down barriers to medication access. These innovative pharmacy constructs do not hold inventory or dispense medications but instead focus on streamlining the patient access journey by serving as a bridge between the HCP and the dispensing pharmacy to benefit patients, HCPs, and manufacturers. "}</BlogP>
    <BlogH2>Patients benefit from a better brand access experience</BlogH2>
    <BlogP>{"Upon receiving the prescription, a non-dispensing pharmacy processes benefit verifications, prior authorizations, copay programs, and any other pre-fulfillment needs before transferring it to a dispensing pharmacy for adjudication and fulfillment. Additionally, since pharmacies are considered HIPAA Covered Entities, HCPs do not have to form a Business Associate Agreement (BAA) to share patient health information. This intermediary can be instrumental in simplifying the patient's treatment journey in an era where "}<BlogA href="https://drugstorenews.com/threats-and-opportunities-facing-retail-pharmacy"><u>dispensing pharmacies are facing challenges on multiple fronts</u></BlogA>{" by enhancing their experience and improving access as follows:"}</BlogP>
    <BlogUL>
      <BlogLI>
        <BlogP>{"Today's patients expect to be active consumers of healthcare services but often lack the "}<BlogA href="/why-transparency-is-critical-in-the-patient-access-journey/"><u>transparency to make informed decisions about a prescribed treatment</u></BlogA>{". Effective, non-dispensing pharmacies can deliver frictionless, consumer-centric experiences offering enhanced transparency that gives patients complete visibility into the status of their prescriptions, ensuringes they are aware of available patient services, and can seamlessly enroll in any copay programs they are eligible for.  "}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP>{"The PA process frequently leaves patients waiting for extended periods of time for a coverage decision, and denials may occur for a host of reasons despite a therapy being appropriately prescribed. These "}<BlogA href="/how-manufacturers-can-improve-speed-to-therapy-overcoming-common-causes-of/"><u>therapy delays</u></BlogA>{" can profoundly impact individuals' health and often result in  "}<BlogA href="https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/iqvia-launch-excellence-viii.pdf"><u>patients abandoning therapy</u></BlogA>{". An integrated, non-dispensing pharmacy that is digitally equipped to manage PAs will help patients get started on their prescribed therapy more quickly and help them stay adherent.  "}</BlogP>
      </BlogLI>
    </BlogUL>
    <BlogH2>HCPs benefit from a seamless prescribing process</BlogH2>
    <BlogP>{"Burdensome PA requirements and staff shortages exacerbate "}<BlogA href="/the-impact-of-time-constrained-hcps-on-life-sciences-commercialization-and/"><u>HCP time constraints</u></BlogA>{" and administrative demands. At the same time, "}<BlogA href="https://www.covermymeds.com/main/medication-access-report/specialty-patient-support/"><u>six out of ten providers report</u></BlogA>{" that they are uncertain of the insurance benefits information needed to start patients on complex therapies. While many HCPs regularly use e-prescribing, many brands still require them to go to a website, download and fill out a form, and fax it to the brand’s hub. All of these factors can negatively impact the adoption of a branded therapy if providers anticipate patient access will be difficult. "}</BlogP>
    <BlogP>{"A tech-enabled, non-dispensing pharmacy can meet HCPs where they are by:   "}</BlogP>
    <BlogUL>
      <BlogLI>
        <BlogP>Integrating seamlessly into their current workflow - accepting e-prescriptions through electronic health records (EHRs) as pharmacies and eliminating the hassle of determining the right pharmacy to utilize based on a patient’s insurance</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP>{"Smoothing the prescribing process by transferring relevant patient information from the EHR to ensure "}<BlogA href="/why-quality-scripts-are-crucial-to-ensuring-pharmacy-coverage-for-your-brand/"><u>quality scripts that are more likely to get coverage</u></BlogA>{" "}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP>{"Alleviating the PA administrative burden by automating and managing the process from start to finish before transferring to the dispensing pharmacy "}</BlogP>
      </BlogLI>
    </BlogUL>
    <BlogH2>Specialty-lite manufacturers need new models to influence brand performance</BlogH2>
    <BlogP>{"Ineffective pharmacy networks can diminish a brand’s reputation, patient and provider satisfaction, health outcomes, and gross-to-net. And "}<BlogA href="/why-strong-market-access-doesnt-always-translate-to-covered-dispenses/"><u>strong market access</u></BlogA>, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers, does not always translate to covered dispenses at the pharmacy.</BlogP>
    <BlogP>{"Access partners that utilize non-dispensing pharmacies can help manufacturers "}<BlogA href="/how-life-science-brands-can-successfully-navigate-retail-challenges/"><u>navigate retail pharmacy challenges</u></BlogA>{" and eliminate the risks of relying on the traditional prescribing process by: "}</BlogP>
    <BlogUL>
      <BlogLI>
        <BlogP><b>Decreasing prescription abandonment</b>{" by ensuring the dispensing pharmacy is contracted with a patient's insurance plan"}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP><b>{"Increasing PA submission and approval rates "}</b>by providing tech-enabled PA Support</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP><b>Improving medication adherence and refill rates</b>{" by supporting better continuity of care"}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP><b>Enabling better decision-making with more visibility into key metrics</b>{" around benefits verification, PAs, health plan PA behavior, and reimbursement rates"}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP><b>Optimizing copay programs for financial sustainability</b>{" by adhering to manufacturer business rules "}</BlogP>
      </BlogLI>
      <BlogLI>
        <BlogP><b>Providing mechanisms to ensure a brand is dispensed as written</b>{" at the retail pharmacy"}</BlogP>
      </BlogLI>
    </BlogUL>
    <BlogH2>Discover the value of an integrated, digital hub platform</BlogH2>
    <BlogP>{"Achieving strong market access for a specialty-lite brand does not guarantee that the patient can access the therapy reliably or affordably. This may explain why more than one "}<BlogA href="https://www2.deloitte.com/us/en/insights/industry/life-sciences/pharmaceutical-market-access.html"><u>of three new drug launches fall short</u></BlogA>{" of expectations. Integrated hubs with non-dispensing pharmacy models can break through these barriers."}</BlogP>
    <BlogP>{"PhilRx is a scalable, end-to-end commercialization platform that helps specialty-lite brands protect their gross-to-net margins while facilitating access, unlocking coverage, and maximizing adherence. Our platform utilizes a non-dispense pharmacy that bridges our digital hub with an integrated nationwide pharmacy network to ensure patients receive prescribed therapy quickly, conveniently, and affordably. Our consultative approach is guided by real-time insights that provide strategic visibility across the prescription journey to improve brand performance. "}</BlogP>
    <BlogP><br /><BlogA href="/demo/"><b><u>{"Book a demo "}</u></b></BlogA>{"of the PhilRx patient access platform today to discover first-hand how your brand can benefit. "}</BlogP>
  </StaticBlogLayout>
);

export default Page;
